Medium-term outcomes of treatments for antibody-associated autoimmune encephalitis

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

Patients with antibody-defined autoimmune encephalitis (including NMDAR, LGI1, CASPR2, IgLON5, GAD65, or GFAP antibodies) will be followed prospectively to compare real-world outcomes of commonly used initial treatment strategies. The observational design enrolls people who are untreated or who have a decision to start treatment within the previous 30 days and records whether they receive first-line therapy alone, first-line plus rituximab, or first-line with dual immunosuppression. Investigators will collect clinical response, need for escalation, and medium-term neurological function from routine care rather than by random assignment. The aim is to document response rates, frequency of non-responders, and patterns of escalation across antibody subtypes to inform future treatment choices.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Adult or child patient with encephalitis defined as anti-GAD, NMDAR, LGI1, CASPR2, IgLON5 or GFAP
* Untreated or with a decision to treat within the previous 30 days.

Exclusion Criteria:

\- Refusal by the referring doctor to participate or refusal by the patient mentioned in the objection to the use of his/her clinical data.

Where it's running

• Hospices Civil de Lyon
  Bron, France Recruiting

Study contacts

• Study coordinator: Bastien Pr JOUBERT
• Email: bastien.joubert@chu-lyon.fr
• Phone: 04 78 86 17 89

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• How vegan, vegetarian, or omnivorous diets relate to blood levels of brain proteins NfL and GFAP

  This study will test whether following a vegan, vegetarian, or omnivorous diet changes blood levels of the brain proteins NfL and GFAP in healthy adults aged 18–40.

  Recruiting Salzburger Landeskliniken · Salzburg, State of Salzburg · NCT07312994

• Long-term effects of NMDAR encephalitis

  This project will use online questionnaires to see if adults who had anti-NMDAR encephalitis experience lasting social, cognitive, or psychological problems.

  Recruiting Hospices Civils de Lyon · Bron · NCT07158229

• Using brain stimulation and digital training to improve cognitive function in older adults

  This study is testing whether a combination of brain stimulation and digital training can help improve thinking skills in older adults with Mild Cognitive Impairment and Alzheimer's Disease.

  Recruiting Universidade Federal do Rio de Janeiro · Rio de Janeiro, Rio de Janeiro · NCT06733714

• National registry for pediatric inflammatory brain diseases in Switzerland

  This study is collecting information on children with inflammatory brain diseases in Switzerland to see how to better diagnose and treat these conditions.

  Recruiting at 12 sites University of Bern · Aarau, Canton of Aargau and 12 other locations · NCT05017142

• ART5803 for people with anti-NMDAR encephalitis or anti-NMDAR autoantibody–linked psychiatric disease

  This will test whether ART5803, a one‑armed antibody, is safe and can help adults with anti‑NMDAR encephalitis or anti‑NMDAR autoantibody‑associated psychiatric symptoms.

  Recruiting Phase 2 Arialys Australia Pty Ltd · Seoul · NCT07093333

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.